As a biomarker, a PAX8/PPARgamma rearrangement is a strong indicator that a tumor is a follicular carcinoma with an early propensity for vascular invasion, but it is not sensitive or specific enough to be used on its own to reliably distinguish between benign and malignant follicular neoplasms. The gene discussed is PAX8; the disease is thyroid gland follicular carcinoma.